George F Vande Woude

List of Publications by Year
in descending order

115 papers	14,967 citations	34016 52 h-index	28224 105 g-index
116 all docs	116 docs citations	116 times ranked	12123 citing authors

#	Article	IF	Citations
1	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 399-412.	1.9	9
2	Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. Journal of Translational Medicine, 2018, 16, 253.	1.8	15
3	Met Activation and Carcinogenesis. Current Human Cell Research and Applications, 2018, , 129-154.	0.1	3
4	<scp>MET</scp>4 expression predicts poor prognosis of gastric cancers with <i>Helicobacter pylori</i> infection. Cancer Science, 2017, 108, 322-330.	1.7	7
5	Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. Molecular Cancer Therapeutics, 2017, 16, 2780-2791.	1.9	23
6	Chromosome instability drives phenotypic switching to metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14793-14798.	3.3	63
7	Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Journal of Translational Medicine, 2015, 13, 306.	1.8	18
8	The MET Receptor Family. , 2015, , 321-358.		2
9	Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2590-2595.	3.3	49
10	MET. , 2014, , 1-6.		0
11	MET. , 2014, , 2761-2765.		0
12	MET: A Critical Player in Tumorigenesis and Therapeutic Target. Cold Spring Harbor Perspectives in Biology, 2013, 5, a009209-a009209.	2.3	105
13	Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes and Cancer, 2013, 4, 247-260.	0.6	35
14	Strengthening Context-Dependent Anticancer Effects on Nonâ€“Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR. Molecular Cancer Therapeutics, 2013, 12, 1429-1441.	1.9	28
15	Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2987-96.	3.3	206
16	MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance. Molecular Cancer Research, 2013, 11, 1112-1121.	1.5	33
17	Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 570-575.	3.3	113
18	RTK inhibition: looking for the right pathways toward a miracle. Future Oncology, 2012, 8, 1397-1400.	1.1	6

#	Article	IF	Citations
19	Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation. PLoS ONE, 2012, 7, e38955.	1.1	17
20	Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4105-4110.	3.3	20
21	MET. , 2011, , 2251-2254.		0
22	Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles. PLoS ONE, 2010, 5, e13586.	1.1	11
23	MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factorâ€"Dependent Fashion to Suppress Carcinoma Growth. Cancer Research, 2010, 70, 6880-6890.	0.4	77
24	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12909-12914.	3.3	105
25	<i>Mig-6</i> modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8677-8682.	3.3	82
26	Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Molecular Cancer Therapeutics, 2009, 8, 2803-2810.	1.9	40
27	Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clinical Cancer Research, 2009, 15, 2207-2214.	3.2	484
28	<i>Met</i> amplification and tumor progression in <i>Cdkn2a</i>â€deficient melanocytes. Pigment Cell and Melanoma Research, 2009, 22, 454-460.	1.5	8
29	A highly invasive human glioblastoma pre-clinical model for testing therapeutics. Journal of Translational Medicine, 2008, 6, 77.	1.8	52
30	c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion. Cancer Research, 2007, 67, 1670-1679.	0.4	239
31	Mig-6, Signal Transduction, Stress Response and Cancer. Cell Cycle, 2007, 6, 507-513.	1.3	90
32	Identification of a Met-Binding Peptide from a Phage Display Library. Clinical Cancer Research, 2007, 13, 6049-6055.	3.2	40
33	Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8995-9000.	3.3	129
34	HGF/SF Increases Tumor Blood Volume: A Novel Tool for the In Vivo Functional Molecular Imaging of Met. Neoplasia, 2006, 8, 344-352.	2.3	10
35	In Vivo Direct Molecular Imaging of Early Tumorigenesis and Malignant Progression Induced by Transgenic Expression of GFP-Met. Neoplasia, 2006, 8, 353-363.	2.3	20
36	Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4046-4051.	3.3	193

#	Article	IF	Citations
37	An alternatively spliced form of Met receptor is tumorigenic. Experimental and Molecular Medicine, 2006, 38, 565-573.	3.2	41
38	HGF/SF-Met signaling in tumor progression. Cell Research, 2005, 15, 49-51.	5.7	160
39	Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene, 2005, 24, 101-106.	2.6	72
40	Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene, 2005, 24, 3697-3707.	2.6	50
41	The distinct stage-specific effects of 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid on the activation of MAP kinase and Cdc2 kinase in Xenopus oocyte maturation. Cellular Signalling, 2005, 17, 507-523.	1.7	5
42	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International Journal of Cancer, 2005, 113, 678-682.	2.3	227
43	Nuclear Imaging of Met-Expressing Human and Canine Cancer Xenografts with Radiolabeled Monoclonal Antibodies (MetSeekTM). Clinical Cancer Research, 2005, 11, 7064s-7069s.	3.2	20
44	Proliferation and invasion: Plasticity in tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10528-10533.	3.3	163
45	Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11740-11745.	3.3	90
46	A Mouse Model of Activating Met Mutations. Cell Cycle, 2005, 4, 518-520.	1.3	25
47	Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment. Clinical Cancer Research, 2004, 10, 3881-3884.	3.2	58
48	Reanalysis of Cancer Drugs. Clinical Cancer Research, 2004, 10, 3897-3907.	3.2	26
49	RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival. Cancer Research, 2004, 64, 7962-7970.	0.4	102
50	Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene, 2004, 23, 5193-5202.	2.6	119
51	Met decoys. Cancer Cell, 2004, 6, 5-6.	7.7	26
52	HGF/SF-met signaling in the control of branching morphogenesis and invasion. Journal of Cellular Biochemistry, 2003, 88, 408-417.	1.2	279
53	Met, metastasis, motility and more. Nature Reviews Molecular Cell Biology, 2003, 4, 915-925.	16.1	2,399
54	Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Experimental Cell Research, 2003, 288, 246-256.	1.2	26

#	Article	IF	Citations
55	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12718-12723.	3.3	321
56	Anthrax Fusion Protein Therapy of Cancer. Current Protein and Peptide Science, 2002, 3, 399-407.	0.7	17
57	Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3052-3057.	3.3	139
58	High expression of the Met receptor in prostate cancer metastasis to bone. Urology, 2002, 60, 1113-1117.	0.5	157
59	Radioimmunoscintigraphy of Tumors Autocrine for Human Met and Hepatocyte Growth Factor/Scatter Factor. Molecular Imaging, 2002, 1, 153535002002000.	0.7	4
60	Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene, 2002, 21, 217-226.	2.6	171
61	An arresting activity. Nature, 2002, 416, 804-805.	13.7	8
62	Radioimmunoscintigraphy of Tumors Autocrine for Human Met and Hepatocyte Growth Factor/Scatter Factor. Molecular Imaging, 2002, 1, 56-62.	0.7	21
63	Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Research, 2002, 62, 589-96.	0.4	108
64	Normal and Malignant Prostate Epithelial Cells Differ in Their Response to Hepatocyte Growth Factor/Scatter Factor. American Journal of Pathology, 2001, 159, 579-590.	1.9	86
65	Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene, 2001, 20, 2761-2770.	2.6	159
66	Inactivation of Lrg-47 and Irg-47 Reveals a Family of Interferon Î³â€"Inducible Genes with Essential, Pathogen-Specific Roles in Resistance to Infection. Journal of Experimental Medicine, 2001, 194, 181-188.	4.2	311
67	Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene, 2000, 19, 2386-2397.	2.6	51
68	Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 2000, 19, 5582-5589.	2.6	382
69	A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene, 2000, 19, 4947-4953.	2.6	308
70	Genes that regulate metastasis and angiogenesis. , 2000, 50, 71-87.		79
71	Hepatocyte growth factorâ€"stimulated invasiveness of monocytes. Blood, 2000, 95, 3964-3969.	0.6	63
72	Regulation of P311 Expression by Met-Hepatocyte Growth Factor/Scatter Factor and the Ubiquitin/Proteasome System. Journal of Biological Chemistry, 2000, 275, 4215-4219.	1.6	38

#	Article	IF	Citations
73	Hepatocyte growth factorâ€“stimulated invasiveness of monocytes. Blood, 2000, 95, 3964-3969.	0.6	29
74	Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor. Journal of Biological Chemistry, 1999, 274, 16377-16386.	1.6	80
75	MEK Wars, a new front in the battle against cancer. Nature Medicine, 1999, 5, 736-737.	15.2	44
76	Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling. Oncogene, 1999, 18, 5120-5125.	2.6	23
77	The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells. Molecular and Cellular Biology, 1999, 19, 5902-5912.	1.1	194
78	Decreased fibronectin expression in Met/HGF-mediated tumorigenesis. Oncogene, 1998, 17, 1179-1183.	2.6	16
79	Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. Oncogene, 1998, 17, 2691-2700.	2.6	39
80	Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes*. Biology of the Cell, 1998, 90, 461-466.	0.7	4
81	Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor. Science, 1998, 280, 734-737.	6.0	992
82	The Inducibly Expressed GTPase Localizes to the Endoplasmic Reticulum, Independently of GTP Binding. Journal of Biological Chemistry, 1997, 272, 10639-10645.	1.6	79
83	Genes involved in oncogenesis. Advances in Veterinary Medicine, 1997, 40, 51-102.	0.6	1
84	Mechanisms of Xenopus oocyte maturation. Methods in Enzymology, 1997, 283, 584-600.	0.4	13
85	Hepatocyte growth factor/scatter factorâ€"Met signaling in tumorigenicity and invasion/metastasis. Journal of Molecular Medicine, 1996, 74, 505-513.	1.7	249
86	Identification of a Novel GTPase, the Inducibly Expressed GTPase, That Accumulates in Response to Interferon Î³. Journal of Biological Chemistry, 1996, 271, 20399-20405.	1.6	110
87	Potential Role of Mitogen-Activated Protein Kinase during Meiosis Resumption in Bovine Oocytes1. Biology of Reproduction, 1996, 55, 1261-1270.	1.2	149
88	Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. Journal of Molecular Medicine, 1996, 74, 505-513.	1.7	62
89	Mos, Meiosis and Cellular Transformation. , 1996, , 59-71.		0
90	[29] Microinjection into Xenopus oocytes. Methods in Enzymology, 1995, 254, 458-466.	0.4	6

#	Article	IF	Citations
91	Mos. , 1995, , 358-360.		0
92	On the loss of Mos. Nature, 1994, 370, 20-21.	13.7	11
93	Mos and the cell cycle: the molecular basis of the transformed phenotype. Current Opinion in Genetics and Development, 1993, 3, 19-25.	1.5	60
94	Meiotic initiation by the mos protein in Xenopus. Nature, 1992, 355, 649-652.	13.7	252
95	Correlation between Physiological and Transforming Activities of thec-mosProto-oncogene Product and Identification of an Essential Mos Domain for These Activities. Japanese Journal of Cancer Research, 1991, 82, 250-253.	1.7	10
96	mos Proto-Oncogene Product and Cytostatic Factor. , 1991, , 112-128.		0
97	<i>Mos</i> Protoâ€Oncogene Function. Novartis Foundation Symposium, 1990, 150, 147-167.	1.2	4
98	Specific proteolysis of the c-mos proto-oncogene product by calpain on fertilization of Xenopus eggs. Nature, 1989, 342, 505-511.	13.7	295
99	The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs. Nature, 1989, 342, 512-518.	13.7	669
100	The Mos proto-oncogene maps near the centromere on mouse chromosome 4. Genomics, 1989, 5, 118-123.	1.3	15
101	Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes. Nature, 1988, 335, 519-525.	13.7	638
102	Proto-oncogene expression in germ cell development. Trends in Genetics, 1988, 4, 183-187.	2.9	95
103	Three additional DNA polymorphisms in the met gene and D7S8 locus: Use in prenatal diagnosis of cystic fibrosis. Journal of Pediatrics, 1987, 111, 490-495.	0.9	31
104	Chromosomal localization of the met proto-oncogene in the mouse and cat genome. Genomics, 1987, 1, 167-173.	1.3	24
105	Mechanism of met oncogene activation. Cell, 1986, 45, 895-904.	13.5	523
106	Expression of c-mos proto-oncogene transcripts in mouse tissues. Nature, 1985, 315, 516-518.	13.7	169
107	The human met oncogene is related to the tyrosine kinase oncogenes. Nature, 1985, 318, 385-388.	13.7	302
108	Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature, 1984, 311, 29-33.	13.7	923

#	Article	IF	Citations
109	Cloning Retroviruses: Retrovirus Cloning?. , 1981, , 89-107.		1
110	Cells transformed by certain strains of moloney sarcoma virus contain murine p60. Cell, 1977, 10, 79-89.	13.5	48
111	Sodium dodecylsulfate-dependent anomalies in gel electrophoresis: Alterations in the banding patterns of foot-and-mouth disease virus polypeptides. Analytical Biochemistry, 1974, 58, 337-346.	1.1	72
112	Isolation of the structural polypeptides of foot-and-mouth disease virus and analysis of their C-terminal sequences. Virology, 1973, 52, 520-528.	1.1	45
113	Chemical and physical properties of foot-and-mouth disease virus: A comparison with maus elberfeld virus. Biochemical and Biophysical Research Communications, 1972, 48, 1222-1229.	1.0	28
114	Number and Molecular Weights of Foot-and-Mouth Disease Virus Capsid Proteins and the Effects of Maleylation. Journal of Virology, 1971, 7, 250-259.	1.5	18
115	MIG-6 and SPRY2 in the Regulation of Receptor Tyrosine Kinase Signaling: Balancing Act via Negative Feedback Loops. , 0, , .		1